The Effect of Benign and Malignant Liver Disease on the Tumour Markers CA19-9 and CEA
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
The serum concentrations of CA19-9 and carcinoembryonic antigen (CEA) were measured in 150 consecutive patients with histologically proven liver disease admitted to a liver unit for transplant assessment. A significant proportion of the cases studied had a CA19-9 above the upper limit of the reference range (35 kU/L): alcoholic liver disease (73%), primary sclerosing cholangitis (61%), primary biliary cirrhosis (60%), chronic hepatitis B (71%), chronic hepatitis C (84%), autoimmune hepatitis (36%) and hepatocellular carcinoma (54%). CEA was only elevated in a small proportion of the patients with benign liver disease and the degree of elevation was small (15-37 μg/L). Significantly raised CEA was observed in two patients (15%) with hepatocellular carcinoma. Statistically significant correlations were observed between the serum CA19-9 concentration and standard parameters of liver dysfunction: positive correlations with aspartate aminotransferase, alkaline phosphatase and bilirubin and negative correlations with albumin and γ-glutamyltransferase. Positive relationships were also observed between CA19-9 and both CEA and creatinine. Both increased production of CA19-9 from biliary epithelial cells and decreased clearance due to cholestasis may be contributing to the elevation of CA19-9 in the bloodstream. Our data indicate that caution is needed in the interpretation of CA19-9 results in the presence of liver dysfunction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis
Ramage, J. K., Donaghy, A., Farrant, J. M., Iorns, R., & Williams, R. (1995) · Gastroenterology · doi:10.1016/0016-5085(95)90462-x · Cited by 279
Cited by
Levy, C., Lymp, J., Angulo, P., Gores, G. J., Larusso, N., & Lindor, K. D. (2005) · Digestive Diseases and Sciences · doi:10.1007/s10620-005-2927-8 · Cited by 339
“Serum levels of CA 19-9 are elevated (above 35 U/ml) in a variety of diseases, including malignant (hepatocellular carcinoma, cholangiocarcinoma) and non-malignant conditions such as alcoholic liver disease, primary sclerosing cholangitis, ascending cholangitis, primary biliary cirrhosis, chronic hepatitis B and C, au…”
BackgroundAdvances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009
Aljiffry, M., Walsh, M. J., & Molinari, M. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.4240 · Cited by 286
Circulating tumor cell isolation for cancer diagnosis and prognosis
Deng, Z., Wu, S., Wang, Y., & Shi, D. (2022) · eBioMedicine · doi:10.1016/j.ebiom.2022.104237 · Cited by 284
Sinakos, E., Saenger, A. K., Keach, J., Kim, W. R., & Lindor, K. D. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.02.007 · Cited by 142
Hultcrantz, R., Olsson, R., Danielsson, Å., Järnerot, G., Lööf, L., Ryden, B. O., Wahren, B., & Broomé, U. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80198-6 · Cited by 107
Metadata
- Authors
- Maestranzi, S., Przemioslo, R., Mitchell, H., & Sherwood, R. A.
- Venue
- Annals of Clinical Biochemistry: International Journal of Laboratory Medicine
- Publisher
- SAGE Publications
- Published
- 1998-01
- Volume
- 35
- Issue
- 1
- Pages
- 99-103
- ISSN
- 0004-5632 (ISSN-L)
- 1758-1001
- OpenAlex
- W2126099677
- Cited by
- 128
- References
- 1
- FWCI
- 2.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Effect of Benign and Malignant Liver Disease on the Tumour Markers CA19-9 and CEA. https://app.cochat.ai/papers/10.1177/000456329803500113
- The paper
- Maestranzi, S., Przemioslo, R., Mitchell, H., & Sherwood, R. A. (1998). The Effect of Benign and Malignant Liver Disease on the Tumour Markers CA19-9 and CEA. Annals of Clinical Biochemistry: International Journal of Laboratory Medicine. https://doi.org/10.1177/000456329803500113
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.